LIFU AUD - Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

Study Basics

Are you over the age of 18 and diagnosed with Alcohol Use Disorder (AUD)? If so, you may be eligible to participate in a feasibility research study to determine if Low-Intensity Focused Ultrasound (LIFU) can be used to change brain activity in a brain region related to alcohol craving.

Study Purpose

The study team is investigating if Low-Intensity Focused Ultrasound (LIFU) can be used to suppress cravings in alcohol use disorder.

Once screening is completed, study participants will undergo two LIFU treatment sessions over two study visits. In one of these sessions, participants will receive LIFU treatment to a key brain area involved in alcohol craving. This brain region is called the ventral striatum. In the other session, you will receive LIFU treatment to a different brain area involved in sensation. This is called ventroposterolateral thalamus and is not usually associated with craving or alcohol use disorder. This is used as a control treatment. You will not be told which treatment you will receive during each of these sessions to control for placebo effects.

Could this study be right for you?

Eligible participants are:

  • Age 18 or older  
  • Diagnosed with Alcohol Use Disorder (AUD)

What participants can expect

This study will require an in-person visit to the research site once a week for five weeks, totaling five study visits. During the first visit, study participants will meet with the study team, review the consent documentation, and complete screening procedures.  The next three visits involve brain scans and/or LIFU treatment. The final visit will be follow-up procedures.

IRB: 24-41884 - Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder

Learn More about LIFU

ClinicalTrials.gov


Contact the Research Team if you are interested in participating

Study Contact Form


Study Personnel

 

Khaled Moussawi, MD, PhD

Principal Investigator

Associate Professor in Residence in the departments of Neurology and Psychiatry at UCSF with extensive experience in substance use disorders and neuromodulation. Dr. Moussawi is board-certified by the American Board of Psychiatry and Neurology.

Google Scholar Profile


Ru Zhang, PhD

Assistant Researcher

Ru Zhang is an assistant professional researcher with a background in cognitive psychology and neuroscience. She received her PhD in mathematical and computational cognitive science from Purdue University.

Google Scholar Profile


Kelly Kadlec, PhD

Postdoctoral Scholar

Kelly Kadlec is a postdoctoral researcher with a background in electrical engineering and neuroscience. She received her PhD in Neurobiology from Caltech.

Google Scholar Profile


Brooke Staveland, PhD

Brooke Staveland, PhD

Postdoctoral Scholar

Brooke Staveland is a postdoctoral researcher with a background in clinical psychology and neuroscience. She received her PhD in Neuroscience from UC Berkeley.

Google Scholar Profile


Sarah Li

Sarah Li, PhD

Postdoctoral Scholar

Sarah Li is a postdoctoral researcher with a background in biomedical engineering and ultrasound tongue imaging, along with an interest in non-invasive measurement for neuropsychiatric disorders. She received her PhD in Biomedical Engineering from the University of Cincinnati.

Google Scholar Profile


Sierra Brandts, BS

Clinical Research Coordinator

Sierra Brandts is a Clinical Research Coordinator with a background in neuromodulation and addiction research. She received her BS in Neuroscience from Sewanee: The University of the South.

 


Emme Chen

Emme Chen, BS

Jr. Research Specialist

Emme Chen is a Jr. Research Specialist with a clinical background in addiction medicine. She received her degree in Biopsychology from UC Santa Barbara.